Loading...
12/16 05:28
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals. Financial performance shows positive trends with increased annual revenue and improved EBITDA, but quarterly metrics are weak, with declining Q4 revenue and margins. Product development shows promise in high-margin areas like radiopharmaceuticals, yet the Q&A reveals uncertainties in data licensing and partnerships. The company's cautious optimism about fiscal '26 and improved cash position are positives, but lack of specific guidance and rising expenses temper enthusiasm. Overall, the mixed financials and unclear growth prospects suggest a neutral short-term stock price reaction.
Total Revenue (Fiscal Year 2025) $57 million, a 14% increase year-over-year from $50.2 million in 2024. The increase was attributed to a combination of disciplined cost execution and revenue growth, including high-margin data revenue.
Research Services Revenue (Fiscal Year 2025) $52.3 million, up 4% year-over-year. This growth reflects the stabilization and renewed momentum in the core services business.
Data Revenue Stream (Fiscal Year 2025) $4.7 million, reflecting initial data licensing deals, which align with the company's strategic focus on high-margin data revenue.
Adjusted EBITDA (Fiscal Year 2025) $7.1 million, compared to an adjusted EBITDA loss of $3.9 million in fiscal 2024. This improvement was driven by revenue growth and disciplined cost management.
Revenue (Q4 2025) $12.1 million, compared to $14 million in Q4 2024. The decline was attributed to lower revenue on a relatively unchanged cost base.
GAAP Operating Loss (Q4 2025) $2 million, compared to a loss of $200,000 in Q4 2024. This included approximately $800,000 in noncash expenses such as stock-based compensation, depreciation, and equipment disposal charges.
Adjusted EBITDA (Q4 2025) Loss of $1.2 million, compared to a gain of $900,000 in Q4 2024. The decline was due to lower revenue and relatively stable costs.
Gross Margin (Q4 2025) 41%, down from 48% in Q4 2024. The decline reflects lower revenue on a relatively unchanged cost base.
Cost of Sales (Fiscal Year 2025) $28.3 million, a 3% decrease from $29.2 million in 2024. This decrease contributed to gross margin expansion.
Gross Margin (Fiscal Year 2025) 50%, up from 42% in 2024. The improvement was driven by high-margin data revenue and operational efficiencies.
Operating Expenses (Fiscal Year 2025) Declined by approximately $3.4 million year-over-year. R&D expenses decreased by $2.7 million, G&A expenses decreased by $1.2 million, while sales and marketing expenses increased by $500,000.
Cash Position (End of Fiscal Year 2025) $9.8 million, up from $2.6 million at the end of fiscal 2024. The increase was driven by operating cash flow and accounts receivable conversion.
Radiopharmaceutical services platform: Launched with expanded radioactive materials license, radiochemistry infrastructure, and screening of over 30 PDX models. Offers integrated radiopharmaceutical workflows including in vitro and ex vivo biodistribution studies and therapeutic efficacy testing.
Data licensing deals: Closed inaugural data licensing deal in Q3, followed by smaller transactions, validating the long-term vision and strategic direction.
Revenue growth and profitability: Achieved record revenue of $57 million in FY 2025, a 14% increase from FY 2024. Adjusted EBITDA swung to $7.1 million from a loss of $3.9 million in FY 2024.
Operational efficiencies: Improved revenue conversion and cost containment led to gross margin expansion to 50% from 42% in FY 2024. Reduced R&D and G&A expenses while increasing sales and marketing investments.
Leadership transition: CEO Ronnie Morris stepping down, with Rob Brainin taking over. Rob brings 25+ years of experience in life sciences and data-driven innovation.
Focus on big pharma relationships: Strengthened relationships with big pharma to ensure resilience through market cycles and engagement in larger multistudy programs.
Macroeconomic headwinds: Biotech and pharma R&D budgets remain constrained, which could impact revenue growth and customer spending.
Customer cancellations: Although there is a decrease in cancellations, the risk of customer cancellations still exists, which could affect bookings-to-revenue conversion rates.
Revenue decline in Q4: The fourth quarter revenue was weaker both sequentially and compared to the same quarter last year, reflecting potential volatility in revenue streams.
Gross margin decline: Gross margin for Q4 dropped to 41% from 48% in the prior year, driven by lower revenue on a relatively unchanged cost base.
Operating loss in Q4: The company recorded a GAAP operating loss of $2 million in Q4, compared to a smaller loss in the prior year, indicating financial challenges in the quarter.
Increased operating expenses: Operating expenses for Q4 rose by 7%, driven by higher sales and marketing costs, which could pressure profitability if not offset by revenue growth.
Dependence on big pharma: The company is focusing on strengthening relationships with big pharma, which are more resilient but could pose a risk if these partnerships do not materialize as expected.
Revenue Projections: The company expects sequential quarterly revenue increases and adjusted EBITDA profit in the next quarter and beyond. Revenue is projected to grow over the next few quarters, along with expanding operating margins.
Cash Flow and Capital Expenditures: The company anticipates remaining cash neutral over the next quarter, with projected cash growth in the second half of the year as revenue increases and margin improvements take hold. No significant capital expenditures are expected this year.
Data Business Growth: The company plans to expand its high-margin data business, which is expected to contribute to revenue growth and profitability.
Market Trends and Customer Behavior: The company has observed early signs of recovery in the biotech and pharma sectors, with a decrease in customer cancellations and an increase in bookings-to-revenue conversion rates. Strengthening relationships with big pharma remains a strategic focus.
Operational Efficiency: The company expects to maintain stable costs while increasing revenue, leading to improved gross margins.
The selected topic was not discussed during the call.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
